From: Hepatitis C virus genotype affects survival in patients with hepatocellular carcinoma
 | Genotype 1 (n = 86) | Genotype 2 (n = 78) | Genotype 3 (n = 16) |
---|---|---|---|
Age, year | 64.5 (56.5–72.3) | 67.5 (60.8–73.0) b | 46.0 (40.0–53.0) c |
Male gender | 63 (73.3%) | 52 (66.7%)b | 15 (93.8%) |
Biopsy for diagnosis | 24 (27.9%) | 27 (34.6%) | 3 (18.8%) |
Diabetes | 27 (33.4%) | 22 (34.9%) | 6 (40.0%) |
Cirrhosis | 77 (89.5%) | 68 (87.2%) | 16 (100%) |
Alcohol > 60 g/day | 4 (4.7%) | 4 (5.1%) | 3 (18.8%) |
SVR | 15 (17.4%) | 18 (23.1%) | 2 (12.5%) |
SVR before enrollment | 5 (5.8%) | 7 (9.0%) | 0 |
SVR after enrollment | 10 (11.6%) | 11 (14.1%) | 2 (12.5%) |
HCV RNA > 600,000 IU/mL | 44 (51.2%) | 29 (37.2%) | 6 (37.5%) |
Creatinine, mg/dL | 0.82 (0.70–0.93) | 0.80 (0.70–0.92) | 0.86 (0.69–0.99) |
Bilirubin, mg/dL | 0.99 (0.72–1.57) | 1.00 (0.75–1.72)b | 1.93 (1.32–3.67)c |
Platelet, × 109/L | 111.5 (71.8–153.8) | 105.5 (81.5–132.3) | 86.5 (43.8–128.8) |
Albumin, g/dL | 3.6 (3.2–4.0) | 3.5 (3.0–3.9)b | 3.0 (2.7–3.6) c |
PT-INR | 1.12 (1.04–1.20) | 1.12 (1.06–1.25)b | 1.35 (1.21–1.58) c |
Child Pugh B or C | 16 (18.2%) | 18 (23.1%) | 10 (62.5%) c |
MELD score | 8.0 (7.0–10.3) | 9.0 (7.0–11.0) b | 12.5 (9.5–16.0) c |
Follow-up period (month) | 28.7 (11.5–45.6) | 31.7 (11.9–64.6) b | 15.0 (4.6–34.9) |